James Harding

2 months ago | targetedonc.com | James Harding

January 30, 2025James J. Harding, MD, discusses the remaining unmet needs in the first-line (1L) treatment space for unresectable hepatocellular carcinoma (uHCC) and how 1L immunotherapy (IO) combinations like nivolumab plus ipilimumab (NIVO + IPI) may help address these gaps, while highlighting unanswered questions and offering clinical pearls for managing uHCC. Video content above is prompted by the following:What are some remaining unmet needs in the 1L space for uHCC?

Jan 23, 2025 | targetedonc.com | James Harding

January 23, 2025James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy (IO) regimens.

Jan 16, 2025 | targetedonc.com | James Harding

January 16, 2025James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.

Jan 9, 2025 | targetedonc.com | James Harding

January 9, 2025James J. Harding, MD, discusses the primary (overall survival [OS]) and secondary end points (overall response rate [ORR], duration of response [DOR]) of the CheckMate 9DW trial, and explores how the inclusion of the lenvatinib (LEN) arm informs the treatment landscape, as well as the safety profiles of first-line systemic immunotherapy in patients with uHCC, focusing on the most significant adverse events seen with nivolumab plus ipilimumab (NIVO + IPI).

Nov 23, 2024 | onclive.com | James Harding

“[This approval] offers a new treatment option for patients with [a] very difficult disease that has notable antitumor activity and…associated safety and tolerability.”James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the significance of the FDA approval of zanidatamab-hrii (Ziihera) for patients with pretreated, unresectable or metastatic HER2-positive biliary tract cancer.